Psoriasis Completed Phase 1 / 2 Trials for Efalizumab (DB00095)

Also known as: PSORIASIS / Psoriasis unspecified / Psoriasis, unspecified

IndicationStatusPhase
DBCOND0013339 (Psoriasis)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00368654Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases EfficacyTreatment